A carregar...

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer

When treating patients with unresectable stage III non-small-cell lung cancer (NSCLC), those with a good performance status and disease measured within a radical treatment volume should be considered for definitive concurrent chemoradiotherapy (cCRT). This guidance is based on key scientific rationa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Autor principal: Conibear, John
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735212/
https://ncbi.nlm.nih.gov/pubmed/33293671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01070-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!